MONT SAINT-HILAIRE, QUEBEC--(MARKET WIRE)--Jun 28, 2006 -- Axcan Pharma Inc. ("Axcan" or the "Company")(TSX:AXP.TO - News)(NasdaqNM:AXCA - News) today announced that in view of further insight provided by post-hoc analyses of the ITAX Phase II and International Phase III trial data, the Company is in contact with the U.S. Food and Drug Administration (the "FDA" or the "Agency") in order to review and evaluate the potential impact of these findings on the statistical analysis plan for the North American pivotal Phase III trial. Accordingly, although the database of the North American Phase III study has been locked, data from this study remain blinded and will not be unblinded until discussions with the FDA are completed. Results of the North American Phase III study, which were expected to be disclosed by June 30, 2006, will now be disclosed when the Company concludes its discussions with the FDA, within a timeframe that is under assessment with the Agency.
